No Data
No Data
Earnings Preview: Moderna to Report Financial Results Pre-market on May 01
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect
Asthma and HIV drugs drive performance growth. GlaxoSmithKline (GSK.US) Q1 profits exceeded expectations, maintaining the annual performance outlook.
The company's profits in the first quarter exceeded expectations, particularly strong sales of asthma and HIV treatment drugs offset the negative impact of the overall vaccine Business line sales performance being below expectations.
Unusual Options Activity: WFC, IP and Others Attract Market Bets, WFC V/OI Ratio Reaches 171.2
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
Express News | CytomX Therapeutics Presents Preclinical Data for Mrna Encoded Masked Il-12 Molecule in Collaboration With Moderna at AACR Annual Meeting